Anticoagulation Management for New Atrial Fibrillation

Stroke Risk Assessment

• The American College of Cardiology recommends using the CHA₂DS₂-VASc score to assess stroke risk in all patients with non-valvular atrial fibrillation, which includes risk factors such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke/TIA, vascular disease, age 65-74 years, and sex category (female) 2
• The European Heart Journal suggests that vascular disease is a risk factor for stroke in patients with atrial fibrillation 1
• The American College of Chest Physicians recommends considering congestive heart failure as a risk factor for stroke in patients with atrial fibrillation 3
• Diabetes mellitus is a risk factor for stroke in patients with atrial fibrillation, according to the American College of Chest Physicians 4
• Prior stroke/TIA is a risk factor for stroke in patients with atrial fibrillation, with a doubled score, as recommended by the American College of Cardiology 2

Anticoagulation Recommendations Based on Risk

Low Risk (CHA₂DS₂-VASc score = 0)

• The American College of Chest Physicians suggests that no anticoagulation therapy is recommended for patients with a CHA₂DS₂-VASc score of 0, but aspirin (75-325 mg daily) may be considered for patients who strongly prefer antithrombotic therapy 4

Intermediate Risk (CHA₂DS₂-VASc score = 1)

• The American College of Chest Physicians recommends oral anticoagulation over no therapy or aspirin for patients with a CHA₂DS₂-VASc score of 1 4

High Risk (CHA₂DS₂-VASc score ≥ 2)

• The American College of Cardiology and the European Heart Journal strongly recommend oral anticoagulation for patients with a CHA₂DS₂-VASc score of 2 or higher, with direct oral anticoagulants (DOACs) preferred over warfarin in eligible patients 1, 2

Choice of Anticoagulant

Direct Oral Anticoagulants (DOACs)

• The American College of Cardiology recommends DOACs as first-line therapy for non-valvular atrial fibrillation in eligible patients, with options including apixaban, dabigatran, rivaroxaban, and edoxaban 1, 2
• The European Heart Journal suggests that apixaban and dabigatran may be preferred for patients with prior gastrointestinal bleeding 3

Vitamin K Antagonists (Warfarin)

• The American College of Chest Physicians recommends a target INR of 2.0-3.0 with time in therapeutic range (TTR) ideally ≥70% for patients on warfarin 3
• Warfarin is preferred in specific situations, such as mechanical heart valves, mitral stenosis, and severe renal impairment, as recommended by the American College of Cardiology 2

Special Considerations

Bleeding Risk

• The American College of Chest Physicians recommends apixaban, edoxaban, or dabigatran 110 mg for patients with prior unprovoked bleeding, warfarin-associated bleeding, or high bleeding risk, as they demonstrate less major bleeding compared to warfarin 3

Renal Function

• The American College of Cardiology recommends dose adjustment of DOACs based on renal function, and warfarin is preferred for patients on dialysis or with end-stage renal disease 2

Cardioversion

• The American College of Chest Physicians recommends therapeutic anticoagulation with warfarin or a DOAC for at least 3 weeks before cardioversion, and continuation of anticoagulation for at least 4 weeks after successful cardioversion 3

Common Pitfalls and Caveats

• The European Heart Journal recommends against discontinuing anticoagulation after successful cardioversion or ablation in patients with stroke risk factors 1
• The American College of Chest Physicians suggests considering switching to a DOAC or implementing additional measures to improve INR control for patients with suboptimal TTR on warfarin (<65%) 3